<DOC>
	<DOCNO>NCT01713686</DOCNO>
	<brief_summary>This prospective , multi-center clinical trial . Enrolled subject receive one Ulthera® treatment decolletage . Follow-up visit occur 90 180 day follow treatment . Study image obtain pre-treatment , immediately post-treatment , follow-up visit .</brief_summary>
	<brief_title>Evaluation Ulthera System Treatment Decolletage</brief_title>
	<detailed_description />
	<criteria>Female , age 35 70 year . Subject good health . Moderate severe skin line wrinkle décolletage ; grade ≥4 chest wrinkle scale . Understands accepts obligation undergo procedure area treat followup period . Willingness ability comply protocol requirement . Subjects childbearing potential must negative urine pregnancy test result must lactate . Absence physical condition unacceptable investigator . Willingness ability provide write consent studyrequired photography . Willingness ability provide write informed consent . Presence active systemic local skin disease may affect wound healing . Scarring area treat . Tattoos area treat . Patients ports defibrillator . Any open wound lesion area . Active severe inflammatory acne region treat . Patients history keloid formation hypertrophic scarring . Inability understand protocol give inform consent . Retinoid , microdermabrasion , prescription level glycolic acid treatment décolletage area within two week prior study participation study . Marked décolletage asymmetry , ptosis , excessive dermatochalasis , deep dermal scarring , thick sebaceous skin . History chronic drug alcohol abuse . History autoimmune disease . Concurrent therapy would interfere evaluation safety effectiveness study device . Subjects anticipate need surgery overnight hospitalization study . Subjects history poor cooperation , noncompliance medical treatment , unreliability . Concurrent enrollment study involve use investigational device drug . Current smoker history smoking last one year . History use follow prescription medication : 1 . Topical Retinoids area within past two week ; 2 . Antiplatelet agents/anticoagulants ( Coumadin , Heparin , Plavix ) . 3 . Psychiatric drug would impair subject understand protocol requirement understand signing informed consent .</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Ulthera® System</keyword>
	<keyword>Ultherapy™ Treatment</keyword>
	<keyword>Ulthera , Inc .</keyword>
	<keyword>Micro-focused Ultrasound Visualization ( MFU-V )</keyword>
</DOC>